| Mark Whyte Md A Professional Medical Corporation | |
|
608 G St Suite 2-b Brawley CA 92227-2568 | |
| (760) 344-3446 | |
| Not Available |
| Full Name | Mark Whyte Md A Professional Medical Corporation |
|---|---|
| Speciality | General Practice |
| Location | 608 G St, Brawley, California |
| Authorized Official Name and Position | Mark R Whyte (PRESIDENT) |
| Authorized Official Contact | 7603443446 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mark Whyte Md A Professional Medical Corporation 608 G St Suite 2-b Brawley CA 92227-2568 Ph: (760) 344-3446 | Mark Whyte Md A Professional Medical Corporation 608 G St Suite 2-b Brawley CA 92227-2568 Ph: (760) 344-3446 |
| NPI Number | 1114137270 |
|---|---|
| Provider Enumeration Date | 05/23/2007 |
| Last Update Date | 03/31/2008 |
| Medicare PECOS PAC ID | 6103925599 |
|---|---|
| Medicare Enrollment ID | O20070626000486 |
News Archive
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of DSP, effective immediately, and the appointment of Saburo Hamanaka as Chairman of Sepracor and Executive Officer of DSP. Sepracor and DSP also announce the planned merger of Sepracor and DSP's subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA), to be completed on April 1, 2010, with Sepracor as the surviving company.
New research by Professor James Jaccard, Ph.D., and Nicole Levitz, M.P.H., of the New York University Silver School of Social Work and its Center for Latino Adolescent and Family Health (CLAFH) has led them to suggest 12 evidence-based principles that can be used to improve contraceptive counseling of adolescents in U.S. health care clinics, doctor's offices, and health service organizations.
A new study published in the journal Clinical & Experimental Allergy reveals that children whose mothers used the popular pain reliever paracetamol during pregnancy were at an increased risk of wheezing when compared to non-users.
The first study to measure the full spectrum of age-related damage to all five senses found that 94 percent of older adults in the United States have at least one sensory deficit, 38 percent have two, and 28 percent have three, four or five.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114137270 | NPI | - | NPPES |
| 00A858890 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | A85889 (California) | Primary |
| Provider Name | Mark R Whyte |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1144255258 PECOS PAC ID: 4284628678 Enrollment ID: I20040408001566 |
News Archive
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of DSP, effective immediately, and the appointment of Saburo Hamanaka as Chairman of Sepracor and Executive Officer of DSP. Sepracor and DSP also announce the planned merger of Sepracor and DSP's subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA), to be completed on April 1, 2010, with Sepracor as the surviving company.
New research by Professor James Jaccard, Ph.D., and Nicole Levitz, M.P.H., of the New York University Silver School of Social Work and its Center for Latino Adolescent and Family Health (CLAFH) has led them to suggest 12 evidence-based principles that can be used to improve contraceptive counseling of adolescents in U.S. health care clinics, doctor's offices, and health service organizations.
A new study published in the journal Clinical & Experimental Allergy reveals that children whose mothers used the popular pain reliever paracetamol during pregnancy were at an increased risk of wheezing when compared to non-users.
The first study to measure the full spectrum of age-related damage to all five senses found that 94 percent of older adults in the United States have at least one sensory deficit, 38 percent have two, and 28 percent have three, four or five.
› Verified 1 days ago
News Archive
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of DSP, effective immediately, and the appointment of Saburo Hamanaka as Chairman of Sepracor and Executive Officer of DSP. Sepracor and DSP also announce the planned merger of Sepracor and DSP's subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA), to be completed on April 1, 2010, with Sepracor as the surviving company.
New research by Professor James Jaccard, Ph.D., and Nicole Levitz, M.P.H., of the New York University Silver School of Social Work and its Center for Latino Adolescent and Family Health (CLAFH) has led them to suggest 12 evidence-based principles that can be used to improve contraceptive counseling of adolescents in U.S. health care clinics, doctor's offices, and health service organizations.
A new study published in the journal Clinical & Experimental Allergy reveals that children whose mothers used the popular pain reliever paracetamol during pregnancy were at an increased risk of wheezing when compared to non-users.
The first study to measure the full spectrum of age-related damage to all five senses found that 94 percent of older adults in the United States have at least one sensory deficit, 38 percent have two, and 28 percent have three, four or five.
› Verified 1 days ago
Sunny R Richley Md Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 751 W Legion Rd Ste 103, Brawley, CA 92227 Phone: 760-351-4400 Fax: 760-351-4407 | |
Brawley Occupational Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 529 E St, Brawley, CA 92227 Phone: 760-344-9000 Fax: 760-344-9191 | |
Motasfa A Hamdy Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 605 W H St, 110, Brawley, CA 92227 Phone: 760-344-7976 | |
George C. Fareed, M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 751 W Legion Rd, Suite #105, Brawley, CA 92227 Phone: 760-344-8750 Fax: 760-344-0558 | |
Clinic Of The Valley Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 195 W Legion Rd, Brawley, CA 92227 Phone: 760-351-8669 | |
Imperial Valley Endocrine Medical Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 528 G St, Brawley, CA 92227 Phone: 760-344-6355 Fax: 760-344-6921 |